Hong Kong – When Mr Au Yat-Gai was worth US$33 billion (S$42 billion) on paper, he was not in his Hong Kong office.
One week later, when his net worth plunged to US$10.1 billion, he was not around either.
Shares of Regencell Bioscience Holdings, the Nasdaq-listed company he founded, have plunged to US$20.19 as at June 27 from a high of US$78 on June 17.
Officers at the headquarters of Regencell said both times that Mr Au makes only short visits there, before turning away reporters.
The traditional Chinese medicine (TCM) company, incorporated in the Cayman Islands, occupies the whole ninth floor of a tower in Hong Kong’s bustling Causeway Bay, including a reception area with a large table tennis table.
Little is known about the tiny, money-losing company whose shares exploded 82,000 per cent higher and suddenly made Mr Au, its chief executive officer with an 86 per cent stake, richer on paper than some of the city’s tycoons like Mr Li Ka-shing.
The fleeting nature of its rip-roaring rally has captivated and mystified observers, from those in the US to Hong Kong.
Morning Brew, a popular business account on social media platform X, flagged its stock move and wondered: “Is there something I’m missing?”
Regulators in the US, which closely monitor wild swings in stock prices, might soon be asking the same question, according to experts.
The Financial Industry Regulatory Authority (Finra), the watchdog for broker-dealers, has repeatedly warned that small, cheap stocks are more susceptible to fraud. These companies can be targets for pump-and-dump schemes in which fraudsters inflate the stock price and quickly sell their shares.
The US Securities and Exchange Commission (SEC), meanwhile, has been increasingly wary about companies listed on US exchanges that are based overseas – and Regencell checks both boxes.
The regulator on June 4 called on the public to weigh in on whether the agency needed to amend the definition of what is called a foreign private issuer, potentially limiting the number of companies that qualify for special status that lets them avoid filing quarterly financial reports or disclosing when executives buy or sell company shares.
“This is an example of very unusual movements in share prices,” said Mr Richard Harris, founder and CEO of Port Shelter Investment Management in Hong Kong. “These movements could certainly trigger interest by investigators.”
The SEC and Finra declined to comment on whether they were monitoring Regencell’s moves.
Regencell did not respond to e-mails and phone calls for comment on its stock performance and its founder’s fortune.
Founded in 2014, Regencell’s main line of business is marketing and licensing traditional treatments for attention deficit hyperactivity disorder (ADHD) and autism spectrum disorder (ASD) developed by the founder’s father, Mr Au Sik-Kee. It has exclusive rights over his traditional medicinal formulas, trademarked under the name Brain Theory.
The firm posted net losses of US$4.4 million and US$6.1 million respectively for the fiscal years ended June 2024 and 2023, according to filings. Its chief medical officer position has been vacant since the last doctor to hold the job resigned in 2022.
The younger Mr Au attended the Haas School of Business at the University of California, Berkeley, and worked at Deutsche Bank in the late 1990s. He suffered from learning disorders and speech problems, and had poor grades and an uncontrollable temper, according to a video post on the company’s Instagram account.
Regencell’s mission is to “improve and save lives using a natural and holistic TCM formula to treat ADHD and ASD”, according to the same video.
The company’s official Instagram account has more than half a million followers. BeOne Medicines, the largest healthcare firm listed in Hong Kong, has just over 2,500. Regencell built up a following with the help of social media campaigns on the platform that offered free tickets for Taylor Swift concerts in the US and Asia.
The firm’s second-largest shareholder is Digital Mobile Venture, a firm ultimately owned by Taiwan’s Mr Samuel Chen and his wife Fiona Chang. Mr Chen was an investor whose early investments in Zoom Video Communications made him a fortune when the company’s stock soared almost 1,500 per cent during the Covid-19 pandemic.
Mr Chen, Ms Chang and their children own a 55 per cent stake in Taipei-based Polaris Group, a biotechnology company developing anti-cancer drugs. He is also the biggest shareholder of Sonix Technology, a provider of integrated circuits listed in Taipei.
On June 18, two men and a woman arrived at Regencell’s Hong Kong office seeking information about treatment for ADHD and dementia. They said they read about the stock’s surge before arriving. The visitors were also turned away. An employee said its staff were not doctors, and directed them to the company’s website.
“Early-stage pharma companies can jump from a dollar to four dollars in 90 seconds if there’s some news about one of their drugs under development doing well in a clinical trial,” said Professor Erik Gordon of the University of Michigan’s Ross School of Business. In this case, “what’s interesting is there’s no news”. BLOOMBERG
Join ST’s Telegram channel and get the latest breaking news delivered to you.
